ARQT: Arcutis Biotherapeutics, Inc. Stock

by  •  • Comments Off on ARQT: Arcutis Biotherapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 987.60
Enterprise Value ($M) 1,101.00
Book Value ($M) 88.67
Book Value / Share 0.77
Price / Book 11.14
NCAV ($M) 77.73
NCAV / Share 0.68
Price / NCAV 12.71

Profitability (mra)
Return on Invested Capital (ROIC) -0.89
Return on Assets (ROA) -0.69
Return on Equity (ROE) -1.88

Liquidity (mrq)
Quick Ratio 6.80
Current Ratio 7.08

Balance Sheet (mrq) ($M)
Current Assets 330.43
Assets 341.37
Liabilities 252.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 59.61
Operating Income -241.10
Net Income -262.14

Cash Flow Statement (mra) ($M)
Cash From Operations -247.06
Cash from Investing 180.23
Cash from Financing 101.32

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-06 13D/A Frazier Life Sciences VIII, L.P. 7.80 0.24
03-06 13G/A Jennison Associates Llc 10.80 33.78
02-14 13G/A Prudential Financial Inc 10.47 2.42
02-13 13G Vanguard Group Inc 5.19
02-13 13G/A Polar Capital Holdings Plc 6.67 -11.52
02-13 13G/A Suvretta Capital Management, Llc 9.99 -0.60
02-12 13G Morgan Stanley 6.50
02-12 13G Rubric Capital Management LP 7.04
01-31 13G Point72 Asset Management, L.P. 5.20 309.88
01-29 13G BlackRock Inc. 6.30 52.47
01-23 13G/A State Street Corp 1.62 -58.55
11-13 13G/A Fmr Llc 3.77 -61.14

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-09-15 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSI
2023-09-15 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TR
2023-09-15 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ T
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 646,966 711,074 90.98
2024-04-25 316,967 757,337 41.85
2024-04-24 324,209 720,102 45.02
2024-04-23 301,036 579,172 51.98

(click for more detail)

Similar Companies
ANAB – AnaptysBio, Inc. ANNX – Annexon, Inc.
APLS – Apellis Pharmaceuticals, Inc. ARVN – Arvinas, Inc.
ARWR – Arrowhead Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io